Our team of dedicated scientists has been working to optimize a range of antibodies for markers which are clinically and diagnostically important. Research frequently necessitates a range of antibodies tailored to the specific needs of each individual project. As such, there is no one specific protocol for IHC that can be used regularly. In clinical perspective, antibodies must be specific with high affinity towards their epitopes, flexible to use, good LOT consistency and reliable. Our Optibody antibodies are carefully validated and fine-tuned with the needs of today’s clinical IHC laboratory. Optibodies™ are validated and optimized using NordiQC recommendations of control tissues and criteria.
| AMACR (BSH-7136-100) | Desmin (BSH-7082-100) |
| AMACR+p63 (BSH-6999-100) | CK5 (CK-HMW) (BSH-7123-100) |
| Androgen Receptor (BSH-7360-100) | ECAD (BSH-7516-100) |
| CD10/Calla (BSH-7021-100) | GCG (BSH-7443-100) |
| CD14 (BSH-7019-100) | HER2 (BSH-7182-100) |
| CD31/PECAM1 (BSH-7112-100) | Ki67 (BSH-7302-100) |
| CD326/EPCAM (BSH-7402-100) | MBP (BSH-7697-100) |
| CEA (BSH-7437-100) | p53 (BSH-7287-100) |
| CK17 (BSH-7311-100) | p63a (BSH-7449-100) |
| CK18 (CK-LMW) (BSH-7235-100) | Pan CK (BSH-7124-100) |
| CK19 (BSH-7240-100) | Vimentin (BSH-7100-100) |
If you have any questions about our Optibodies™ please contact us and one of our product specialists will get back to you as soon as possible.
Laboratory services with excellence
BioSiteHisto is focused on tissue- and cell-based technologies. Our high-quality service includes histology, IHC, in vitro research, & in vitro testing. We are fully compliant with international Good Laboratory Practice standards and certified by the Finnish Medicines Agency FIMEA.